Cary C. Cotton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cary C. Cotton has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Evan S. Dellon
Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
6 shared publications - Mousumi Biswas
Centre for Reviews and Dissemination, University of York, York, UK
2 shared publications Nicholas J. Shaheen
Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
2 shared publications- Nicholas J. Shaheen
Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, North Carolina
2 shared publications Swathi Eluri
Department of Medicine, Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, University of North Carolina At Chapel Hill, Chapel Hill, USA
2 shared publicationsA Estrada
1 shared publication
Latest Publications
- 17 January 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (2) , 217-228
Prospective cohort study of palliative treatment of esophageal cancer with liquid nitrogen spray cryotherapy
- 17 January 2026
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 104 (2) , 217-228
Prospective cohort study of palliative treatment of esophageal cancer with liquid nitrogen spray cryotherapy
- 9 December 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (9) , 2149-2157
An Eosinophilic Esophagitis Endoscopic Reference Score Threshold of 2 or Less Is Robust for Assessing Endoscopic Response to Treatment of Eosinophilic Esophagitis
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.
- 9 December 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (9) , 2149-2157
An Eosinophilic Esophagitis Endoscopic Reference Score Threshold of 2 or Less Is Robust for Assessing Endoscopic Response to Treatment of Eosinophilic Esophagitis
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.
- 27 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 905-908
Health State Utility is Substantially Reduced With an Increasing Burden of Patient-Reported Symptoms in Eosinophilic Esophagitis
INTRODUCTION: We aimed to estimate health state utility in eosinophilic esophagitis (EoE) by histologic activity and assess association with disease parameters. METHODS: In this cross-sectional study, we measured health state utility by time trade-off and assessed symptoms with the EoE Symptom Activity Index. RESULTS: In 51 adults with EoE, the mean utility was 0.91 (95% CI 0.86, 0.95). Utility was numerically worse in patients with dilation or a smaller stricture diameter. With each ten-point improvement in EoE Symptom Activity Index, utility increased by 0.03 (95% CI 0.01, 0.05). DISCUSSION: EoE is associated with reduced health state utility, with symptoms most strongly predicting valuation.
- 27 September 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (4) , 905-908
Health State Utility is Substantially Reduced With an Increasing Burden of Patient-Reported Symptoms in Eosinophilic Esophagitis
INTRODUCTION: We aimed to estimate health state utility in eosinophilic esophagitis (EoE) by histologic activity and assess association with disease parameters. METHODS: In this cross-sectional study, we measured health state utility by time trade-off and assessed symptoms with the EoE Symptom Activity Index. RESULTS: In 51 adults with EoE, the mean utility was 0.91 (95% CI 0.86, 0.95). Utility was numerically worse in patients with dilation or a smaller stricture diameter. With each ten-point improvement in EoE Symptom Activity Index, utility increased by 0.03 (95% CI 0.01, 0.05). DISCUSSION: EoE is associated with reduced health state utility, with symptoms most strongly predicting valuation.
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
1135 HEALTH STATE UTILITY IS SUBSTANTIALLY REDUCED IN EOSINOPHILIC ESOPHAGITIS AND IS MOST ASSOCIATED WITH PATIENT-REPORTED SYMPTOMS
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
1135 HEALTH STATE UTILITY IS SUBSTANTIALLY REDUCED IN EOSINOPHILIC ESOPHAGITIS AND IS MOST ASSOCIATED WITH PATIENT-REPORTED SYMPTOMS
- 15 April 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (7) , 1056-1062
Surveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most
INTRODUCTION: Endoscopic eradication therapy with radiofrequency ablation (RFA) and endoscopic mucosal resection is a safe and effective treatment for Barrett's esophagus. Although the outcomes of surveillance endoscopy after successful endoscopic eradication therapy have been described, no previous studies have modeled the natural history or the effect of surveillance endoscopy after successful ablation to prevent progression to invasive esophageal adenocarcinoma. METHODS: The US RFA Registry is a multicenter registry consisting of patients treated with RFA for Barrett's esophagus at 148 institutions (113 community-based and 35 academic-affiliated). The authors fit models to impute the natural history of recurrence and neoplastic progression after any recurrence or retreatment. Natural history estimates of invasive adenocarcinoma after ablation therapy were compared with as-treated estimates at 5 years to derive the preventive risk difference for surveillance. RESULTS: Natural history estimates for the postablation progression of high-grade dysplasia (HGD) or intramucosal adenocarcinoma to invasive adenocarcinoma after treatment were 6.3% at 5 years compared with 1.3% for low-grade dysplasia (LGD). The natural history model found a much higher preventative risk difference for surveillance for HGD/intramucosal adenocarcinoma (−4.8%), compared with LGD (−1.1%). The numbers needed to surveil at 5 years were 21 and 90 for these groups, respectively, to prevent one case of invasive esophageal adenocarcinoma, making surveillance after successful ablation of baseline HGD more than 4 times as effective at preventing invasive cancer than after successful ablation of baseline LGD. DISCUSSION: Endoscopic surveillance after successful ablation of baseline HGD or intramucosal cancer is much more effective than surveillance after successful treatment of baseline LGD in averting invasive adenocarcinoma. Although the modest benefits of surveillance for treated LGD may be greater than the risks for patients at average risk for adverse effects of endoscopy, clinicians should concentrate on retaining patients with baseline HGD or cancer in endoscopic surveillance programs.
- 15 April 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 117 (7) , 1056-1062
Surveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most
INTRODUCTION: Endoscopic eradication therapy with radiofrequency ablation (RFA) and endoscopic mucosal resection is a safe and effective treatment for Barrett's esophagus. Although the outcomes of surveillance endoscopy after successful endoscopic eradication therapy have been described, no previous studies have modeled the natural history or the effect of surveillance endoscopy after successful ablation to prevent progression to invasive esophageal adenocarcinoma. METHODS: The US RFA Registry is a multicenter registry consisting of patients treated with RFA for Barrett's esophagus at 148 institutions (113 community-based and 35 academic-affiliated). The authors fit models to impute the natural history of recurrence and neoplastic progression after any recurrence or retreatment. Natural history estimates of invasive adenocarcinoma after ablation therapy were compared with as-treated estimates at 5 years to derive the preventive risk difference for surveillance. RESULTS: Natural history estimates for the postablation progression of high-grade dysplasia (HGD) or intramucosal adenocarcinoma to invasive adenocarcinoma after treatment were 6.3% at 5 years compared with 1.3% for low-grade dysplasia (LGD). The natural history model found a much higher preventative risk difference for surveillance for HGD/intramucosal adenocarcinoma (−4.8%), compared with LGD (−1.1%). The numbers needed to surveil at 5 years were 21 and 90 for these groups, respectively, to prevent one case of invasive esophageal adenocarcinoma, making surveillance after successful ablation of baseline HGD more than 4 times as effective at preventing invasive cancer than after successful ablation of baseline LGD. DISCUSSION: Endoscopic surveillance after successful ablation of baseline HGD or intramucosal cancer is much more effective than surveillance after successful treatment of baseline LGD in averting invasive adenocarcinoma. Although the modest benefits of surveillance for treated LGD may be greater than the risks for patients at average risk for adverse effects of endoscopy, clinicians should concentrate on retaining patients with baseline HGD or cancer in endoscopic surveillance programs.
- 18 May 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (2) , 367-376
Gender and Nationality Trends in Manuscripts Published in Prominent Gastroenterology Journals Between 1997 and 2017
Background Gender disparities remain in the field of gastroenterology (GI) despite the decreasing gender gap in the medical field overall. We sought to examine primary and last female authorship as a marker of academic opportunity and advancement to assess the proportion of women publishing in GI over 20 years (1997–2017). Methods In this observational study, we assessed the gender and nationality of primary and last authors of original research manuscripts in three GI journals (Gastroenterology, Gut, and American Journal of Gastroenterology) across a 20-year period in 5-year intervals (in 1997, 2002, 2007, and 2012). We used a validated gender-determining algorithm, genderize.io, to classify gender. Our primary outcome was the proportion of female primary and last authors, with secondary measures assessing trends in gender and nationality. Results Through the Genderize.io gender database, we were able to identify the gender for 3,673 (95.9%) of primary author names and 3,504 (95.4%) of last author names in the 3,615 manuscripts evaluated. Overall, there was a significant increase in female primary authors over time, from 18.1% in 1997 to 42.6% in 2017, a 6.0% increase per 5-year period (95% CI 4.8–7.2%). A similar trend was found for female last authors, however, at a slower rate, from 8.3% in 1997 to 24.7% in 2017, a 3.5% increase per 5 years (95% CI 2.5–4.4%). These trends were noted cumulatively, and in each journal individually. Manuscripts with a female last author were more likely to demonstrate a female primary author. Conclusion Female authorship in high-impact gastroenterology journals has increased over time. Last authorship has lagged primary authorship in female representation and has increased more slowly over time. Interventions to reduce gender disparity in GI research should focus on the transition from first to last authorship.
- 18 May 2021
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 67 (2) , 367-376
Gender and Nationality Trends in Manuscripts Published in Prominent Gastroenterology Journals Between 1997 and 2017
Background Gender disparities remain in the field of gastroenterology (GI) despite the decreasing gender gap in the medical field overall. We sought to examine primary and last female authorship as a marker of academic opportunity and advancement to assess the proportion of women publishing in GI over 20 years (1997–2017). Methods In this observational study, we assessed the gender and nationality of primary and last authors of original research manuscripts in three GI journals (Gastroenterology, Gut, and American Journal of Gastroenterology) across a 20-year period in 5-year intervals (in 1997, 2002, 2007, and 2012). We used a validated gender-determining algorithm, genderize.io, to classify gender. Our primary outcome was the proportion of female primary and last authors, with secondary measures assessing trends in gender and nationality. Results Through the Genderize.io gender database, we were able to identify the gender for 3,673 (95.9%) of primary author names and 3,504 (95.4%) of last author names in the 3,615 manuscripts evaluated. Overall, there was a significant increase in female primary authors over time, from 18.1% in 1997 to 42.6% in 2017, a 6.0% increase per 5-year period (95% CI 4.8–7.2%). A similar trend was found for female last authors, however, at a slower rate, from 8.3% in 1997 to 24.7% in 2017, a 3.5% increase per 5 years (95% CI 2.5–4.4%). These trends were noted cumulatively, and in each journal individually. Manuscripts with a female last author were more likely to demonstrate a female primary author. Conclusion Female authorship in high-impact gastroenterology journals has increased over time. Last authorship has lagged primary authorship in female representation and has increased more slowly over time. Interventions to reduce gender disparity in GI research should focus on the transition from first to last authorship.
- 1 June 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (6) , 1142-1148
The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis
- 1 June 2016
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 83 (6) , 1142-1148
The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis